Regorafenib for Metastatic Colorectal Cancer: An Analysis of a Registry-Based Cohort of 555 Patients.

Alena Novakova-JiresovaKaterina KopeckovaLudmila BoublikovaRenata ChloupkovaBohuslav MelicharLubos PetruzelkaJindrich FinekOndrej FialaPeter GrellStanislav BatkoZdenek LinkeIgor KissJana PrausovaTomas Buchler

Published in: Cancer management and research (2020)

OS of patients treated with regorafenib in the real-world clinical practice in this cohort exceeded that reported in randomized trials. Regorafenib is a safe and active treatment option for a subgroup of patients with mCRC who are progressing after other systemic therapies and maintain good performance status.

Keyphrases

metastatic colorectal cancer
end stage renal disease
clinical practice
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
patient reported outcomes
study protocol